News | August 06, 2025
Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr
Cenexi reports an EBITDA breakeven for the quarter
Cenexi reports an EBITDA breakeven for the quarter
This will be Aster’s fifth hospital in Bengaluru
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories
The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
Godavari Biorefineries receives patent from CNIPA
Subscribe To Our Newsletter & Stay Updated
